Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Stage IV Non-small Cell Lung Cancer|Stage IV Melanoma|Triple Negative Breast Cancer|Renal Cell Carcinoma Stage IV
Interventions: COMBINATION_PRODUCT: ImmunicomAIAC
Sponsor: Dr. Ronnie Shapira
Collaborators: Immunicom Inc. San Diego California, USA